Silence Therapeutics (SLN)
(Delayed Data from NSDQ)
$5.95 USD
-0.22 (-3.57%)
Updated Aug 4, 2025 04:00 PM ET
4-Sell of 5 4
C Value F Growth B Momentum F VGM
Fundamental Charts
About Market Cap
As of the previous market close, Silence Therapeutics PLC Sponsored ADR has a market cap of $172.09M, which represents its share price of $5.75 multiplied by its outstanding shares number of 29.93M. As a small-cap company, SLN's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
SLN 5.95 -0.22(-3.57%)
Will SLN be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for SLN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SLN
Beat the Market the Zacks Way: Credo, Palantir, Oracle in Focus
Wall Street Analysts Think Silence Therapeutics (SLN) Could Surge 556.19%: Read This Before Placing a Bet
SLN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts Believe Silence Therapeutics (SLN) Could Rally 590.66%: Here's is How to Trade
Silence Therapeutics (SLN) Upgraded to Buy: Here's What You Should Know
SLN Stock Down Despite Cholesterol Drug Lowering Lipoprotein Levels
Other News for SLN
Silence Therapeutics Passes Key Resolutions at AGM
SLN: HC Wainwright & Co. Reiterates Buy Rating on Silence Therapeutics | SLN Stock News
SLN: Chardan Capital Maintains Buy Rating and $35 Price Target for Silence Therapeutics | SLN ...
Buy Rating on Silence Therapeutics: Promising Developments in Divesiran and Zerlasiran Programs
Promising Phase 1 Data and Strong Mechanistic Rationale Justify Buy Rating for Silence Therapeutics’ Divesiran in Polycythemia Vera